Related Experiment Video
Updated: Feb 16, 2026
10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
39.7K
Summary
Talazoparib, a PARP inhibitor, shows promise for patients with advanced HER2-negative breast cancer and BRCA mutations. The drug improved progression-free survival and quality of life compared to chemotherapy.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Advanced or metastatic HER2-negative breast cancer is a challenging diagnosis.
- Germline BRCA1/2 mutations are associated with specific breast cancer subtypes.
- Chemotherapy remains a standard treatment but has limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of talazoparib in patients with advanced or metastatic HER2-negative breast cancer and germline BRCA1/2 mutations.
- To compare talazoparib with physician's choice of chemotherapy.
Main Methods:
- Phase III clinical trial.
- Patients randomized to receive talazoparib or chemotherapy.
- Progression-free survival, overall survival, and quality of life were assessed.
Main Results:
- Talazoparib demonstrated improved progression-free survival compared to chemotherapy.
- A subset of patients treated with talazoparib achieved complete responses.
- Talazoparib treatment led to enhanced patient quality of life.
Conclusions:
- Talazoparib is a potential therapeutic option for patients with advanced or metastatic HER2-negative breast cancer and germline BRCA1/2 mutations.
- The PARP inhibitor offers benefits in terms of survival and quality of life over traditional chemotherapy.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
02:34Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
01:21Cancer Survival Analysis
784
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
784